The Janssen Pharmaceutical Companies of Johnson & Johnson announces New Analyses Suggest Favorable Results for STELARA? (ustekinumab) When Used as a First-Line Therapy for Bio-Na?ve Patients with Moderately to Severely Active Crohn's Disease and Ulcerative Colitis
October 25, 2021 at 08:07 am EDT
Share
The Janssen Pharmaceutical Companies of Johnson & Johnson announced data from two new analyses of STELARA? (ustekinumab) for the treatment of adults with moderately to severely active Crohn's disease (CD) and ulcerative colitis (UC). In a modelled analysis focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was when STELARA was used as a first-line advanced therapy for bio-na?ve patients with moderately to severely active UC relative to outcomes associated with second- or third-line use (P0540). Additionally, in a separate real-world claims analysis, a greater proportion of bio-na?ve patients who started biologic therapy with STELARA (n=948) for moderately to severely active CD showed persistence at 12 months versus adalimumab (n=4,143) (P0525). These data are among 16 abstracts, including one oral presentation, presented at the 2021 American College of Gastroenterology Annual Scientific Meeting, which is taking place October 22-27 in Las Vegas, Nevada. Initiating STELARA as a first-line advanced therapy for UC in a hybrid decision tree model resulted in more favorable patient outcomes in terms of increased amount of time spent in remission or response and the postponing of surgery compared with second-line and third-line use. When used first-line, STELARA-treated patients in the cohort model spent on average: 8.5 months (71% of the time) in remission or response over one year. 23.1 months (64% of the time) in remission or response over three years. 32.2 months (54% of the time) in remission or response over five years. When STELARA was used in the second-line setting, patients spent on average: 7.9 months (66% of the time) in remission or response over one year.14.5 months (40% of the time) in remission or response over three years.17.5 months (29% of the time) in remission or response over five years. Modelled use of STELARA in the first- versus second-line reduced time affected by active UC by 0.6, 8.3, and 13.8 months over one, three, and five years, respectively. When compared to third-line, first-line use of STELARA suggested even greater reductions at the one-year (0.9 months), three-year (9 months), and five-year (14.5 months) timepoints. Future research is required to generate long-term clinical data to confirm these results.
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows:
- pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.;
- medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals;
- consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc.
At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25).
Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
The Janssen Pharmaceutical Companies of Johnson & Johnson announces New Analyses Suggest Favorable Results for STELARA? (ustekinumab) When Used as a First-Line Therapy for Bio-Na?ve Patients with Moderately to Severely Active Crohn's Disease and Ulcerative Colitis